Coronary stent Eurolimus™

cobalt-chromiumdrug eluting

The EUROLIMUS™ Sirolimus eluting coronary stent system is made of a coated cobalt-chromium alloy (L605) stent and a rapid-exchange catheter. Eurolimus is indicated for use in patients with symptomatic ischemic coronary heart disease due to de novo lesions or restenosed lesions of the coronary arteries. The stent system is also indicated for the treatment of acute or suspected occlusions in patients who respond unsuccessfully to an interventional therapy following balloon dilatation. Effective & controlled Sirolimus release The Sirolimus drug is formulated in a special polymer coating which guarantuees controlled release through the healing period following coronary intervention. A simultaneous polymer resorption and drug release takes place within 3-4 months to match the procedure–triggered biological response. As a result, EUROLIMUS™ achieves drug release over the entire restenotic cascade. Bioabsorbable Polymere The sirolimus is formulated in a PLGA 85/15 poly(lactide-co-glycolide) Coplymere coating. Both substances – the copolymer and also the homopolymers – are generally considered as non toxic and biocompatible. The two natural materials are fully decomposed to water and carbon dioxide between 10-13 weeks. The coating solution is applied to the stent through asymmetric coating. Here, the thickness of the coating layer is reduced on the luminal side of the device compared to an increased amount on the abluminal side. This asymmetric coating technique is balanced around optimal drug transfer to the vessel.